These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22571785)

  • 1. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.
    Andrés JI; De Angelis M; Alcázar J; Celen S; Bormans G
    Curr Top Med Chem; 2012; 12(11):1224-36. PubMed ID: 22571785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.
    Schröder S; Scheunemann M; Wenzel B; Brust P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012.
    Schröder S; Wenzel B; Deuther-Conrad W; Scheunemann M; Brust P
    Molecules; 2016 May; 21(5):. PubMed ID: 27213312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of phosphodiesterase as cancer therapeutics.
    Peng T; Gong J; Jin Y; Zhou Y; Tong R; Wei X; Bai L; Shi J
    Eur J Med Chem; 2018 Apr; 150():742-756. PubMed ID: 29574203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Discovery of PDEs Inhibitors.
    Li L; Chen W; Chen T; Ren J; Xu Y
    Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase.
    Chen Q; Xia Y; Liu HN; Chi Y; Li X; Shan LS; Dai B; Zhu Y; Wang YT; Miao X; Sun Q
    Eur J Med Chem; 2024 Nov; 277():116769. PubMed ID: 39163778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
    Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
    J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
    Brescia M; Zaccolo M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of phosphodiesterases in schizophrenia : therapeutic implications.
    Siuciak JA
    CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
    Sutor B; Mantell K; Bacher B
    Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a series of novel carbon-11 labeled PDE10A inhibitors.
    Stepanov V; Miura S; Takano A; Amini N; Nakao R; Hasui T; Nakashima K; Taniguchi T; Kimura H; Kuroita T; Halldin C
    J Labelled Comp Radiopharm; 2015 May; 58(5):202-8. PubMed ID: 25891816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.
    Andrés JI; De Angelis M; Alcázar J; Iturrino L; Langlois X; Dedeurwaerdere S; Lenaerts I; Vanhoof G; Celen S; Bormans G
    J Med Chem; 2011 Aug; 54(16):5820-35. PubMed ID: 21777010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-Protein Interactions of Phosphodiesterases.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2019; 19(7):555-564. PubMed ID: 30931862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
    Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4.
    Parker CA; Matthews JC; Gunn RN; Martarello L; Cunningham VJ; Dommett D; Knibb ST; Bender D; Jakobsen S; Brown J; Gee AD
    Synapse; 2005 Mar; 55(4):270-9. PubMed ID: 15668983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors.
    Palacios JM; Beleta J; Segarra V
    Farmaco; 1995 Dec; 50(12):819-27. PubMed ID: 8634072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.